Obese Clinical Trial - Arginase Inhibition in Humans With Obesity

Status Completed

Clinical Trial Summary

To evaluate the efficacy of arginase inhibition on endothelial function in humans with obesity.

Clinical Trial Description

The study is performed on one group of subjects with body mass index >35 and the absence of type 2 diabetes. Inclusion criteria: Body mass index >35 kg/m2. Exclusion criteria: Age >80 years. Type 2 diabetes defined as >7 mmol/L in fasting plasma glucose or >11 mmol/L following 2h of oral glycemic load. Myocardial infarction/unstable angina within 6 weeks prior to the study. Treatment with oral anticoagulants (Warfarin or New oral anticoagulants), Raynaud's phenomenon, peripheral vasculopathies, arterial shunting or other vascular surgery of the study arm. Any concomitant disease or condition that may interfere with the possibility for the patient to comply with or complete the study protocol. Participant in an ongoing study. Unwillingness to participate following oral and written information. Forearm blood flow is determined by venous occlusion plethysmography. Endothelium-dependent vasodilatation is determined during intra-brachial artery infusion of serotonin (21, 70 and 210 ng/min). Endothelium-independent vasodilatation is determined by infusion of sodium nitroprusside (SNP; 1, 3 and 10 µg/min). Each dose is given for 2 min at a rate of 2.5 ml/min. Data are expressed as percentage change in forearm blood from baseline flow. Fifteen subjects are included. On the day of the study the subject arrives to the laboratory after having a light breakfast. Forearm vessels of the non-dominant arm are cannulated and forearm blood flow is determined as described above. Baseline endothelium-dependent and endothelium-independent vasodilatation is determined by intra-arterial infusions of serotonin and SNP, respectively. Thereafter an intra-arterial infusion of the arginase inhibitor N-omega-hydroxy-nor-l-arginine (nor-NOHA) is administered as an intra-arterial infusion at a rate of 0.1 mg/min and is maintained for 120 min. The dose is based on a previous study by our group demonstrating improved endothelial function. Endothelium-dependent and -independent vasodilatation is reassessed at 120 min of infusion. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT05536934
Study type	Interventional
Source	Karolinska Institutet
Contact
Status	Completed
Phase	Early Phase 1
Start date	December 2016
Completion date	March 2022

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT04105075` - COPD in Obese Patients
Completed	`NCT04099654` - The Effect of Core Stabilization Exercise Program in Obese Subjects Awaiting Bariatric Surgery	N/A
Recruiting	`NCT05857150` - Exercise Response in Humans With Obesity
Completed	`NCT03532672` - Early Effect of Fasting on Metabolic, Inflammatory, and Behavioral Responses in Females With and Without Obesity	N/A
Completed	`NCT02618486` - The Effects of Obesity on Non Surgical Periodontal Therapy	N/A
Completed	`NCT02086448` - Sleep Disordered Breathing, Obesity and Pregnancy Study (SOAP)	N/A
Completed	`NCT01724502` - Mitochondrial Dysfunction in Diabetes	N/A
Completed	`NCT01724515` - PGC-1 and Mitochondrial Dysfunction in Diabetes	N/A
Active, not recruiting	`NCT01634204` - Efficacy of a Web-based Weight Loss Program	Phase 2
Completed	`NCT01479933` - Glucose Metabolism Effects of Vitamin D Supplementation in Prediabetes	N/A
Completed	`NCT01421589` - Growth Hormone Treatment on Phosphocreatine Recovery in Obesity	N/A
Completed	`NCT01467817` - Obesity/Overweight in Persons With Early and Chronic Spinal Cord Injury (SCI)	N/A
Completed	`NCT03528304` - Native Women's Wellness: Contingency Management for Tobacco Cessation and Weight Loss	N/A
Completed	`NCT01726647` - Metabolism Associated With Abdominal Fat Mass Distribution	N/A
Active, not recruiting	`NCT02125149` - The Expecting Study	N/A
Completed	`NCT05737927` - Pharmacodynamics and Pharmacokinetics of Different Glucose Bead Formulations in Obese Healthy Subjects	Phase 1
Completed	`NCT05433506` - Safety and Pharmacokinetics of HU6	Phase 1
Completed	`NCT02871882` - Ox Bile- Conjugated Bile Acids Sodium in Type II Diabetes Mellitus	Phase 2
Completed	`NCT03298464` - Study of NGM313 in Obese Participants	Phase 1
Completed	`NCT05061173` - Comparison of Aerobic, Resistance, and Combined Training in Overweight/Obese Hypertensive Adults	N/A

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.